[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2019000189A1 - Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481) - Google Patents

Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)

Info

Publication number
CL2019000189A1
CL2019000189A1 CL2019000189A CL2019000189A CL2019000189A1 CL 2019000189 A1 CL2019000189 A1 CL 2019000189A1 CL 2019000189 A CL2019000189 A CL 2019000189A CL 2019000189 A CL2019000189 A CL 2019000189A CL 2019000189 A1 CL2019000189 A1 CL 2019000189A1
Authority
CL
Chile
Prior art keywords
methods
new anti
divisional application
antibodies
claudin antibodies
Prior art date
Application number
CL2019000189A
Other languages
English (en)
Inventor
Sarah Fong
Vikram Natwarsinhji Sisodiya
Robert A Stull
Samuel A Williams
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CL2019000189A1 publication Critical patent/CL2019000189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EN LA PRESENTE SE PROVEEN NUEVOS ANTICUERPOS Y CONJUGADOS DE ANTICUERPO Y FÁRMACO ANTI-CLDN (ADC), INCLUYENDO A DERIVADOS DE LOS MISMOS, Y MÉTODOS PARA USAR LOS MISMOS PARA TRATAR TRAST ORNOS PROLIFERATIVOS.
CL2019000189A 2015-12-04 2019-01-24 Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481) CL2019000189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04
US201662427027P 2016-11-28 2016-11-28

Publications (1)

Publication Number Publication Date
CL2019000189A1 true CL2019000189A1 (es) 2019-06-07

Family

ID=58797837

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018001481A CL2018001481A1 (es) 2015-12-04 2018-06-01 Nuevos anticuerpos anti-claudina y sus métodos de uso
CL2019000189A CL2019000189A1 (es) 2015-12-04 2019-01-24 Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001481A CL2018001481A1 (es) 2015-12-04 2018-06-01 Nuevos anticuerpos anti-claudina y sus métodos de uso

Country Status (23)

Country Link
US (1) US20190083645A1 (es)
EP (1) EP3383917A4 (es)
JP (1) JP2019500335A (es)
KR (1) KR20180088445A (es)
CN (1) CN108473588A (es)
AU (1) AU2016364853A1 (es)
BR (1) BR112018011319A2 (es)
CA (1) CA3006738A1 (es)
CL (2) CL2018001481A1 (es)
CO (1) CO2018005752A2 (es)
CR (1) CR20180348A (es)
DO (1) DOP2018000138A (es)
EC (1) ECSP18049762A (es)
HK (1) HK1254743A1 (es)
IL (1) IL259681A (es)
MA (1) MA43385A (es)
MX (1) MX2018006782A (es)
PE (1) PE20181302A1 (es)
PH (1) PH12018501153A1 (es)
RU (1) RU2018124319A (es)
SG (1) SG11201804673WA (es)
TW (1) TW201726175A (es)
WO (1) WO2017096163A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CN109790222B (zh) 2016-07-08 2022-03-15 克莱格医学有限公司 抗密蛋白18a2的抗体及其应用
RS62928B1 (sr) * 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3073331A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
RU2020112280A (ru) * 2017-09-02 2021-10-05 Эббви Инк. Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US20210283141A1 (en) * 2018-05-25 2021-09-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
BR112021016056A2 (pt) * 2019-02-15 2021-12-14 Integral Molecular Inc Anticorpos de claudina 6 e usos dos mesmos
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
WO2020196474A1 (ja) 2019-03-25 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CN115998901A (zh) 2019-11-05 2023-04-25 礼新医药科技(上海)有限公司 靶向紧密连接蛋白18.2的抗体药物偶联物
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063758A1 (en) * 2003-12-31 2005-07-14 Council Of Scientific And Industrial Research C2-FLUORO PYRROLO[2,1-c][1,4]BENZODIAZEPINE DIMERS
US7189710B2 (en) * 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
CN103068405A (zh) * 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
KR101645905B1 (ko) * 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CA2928671A1 (en) * 2013-11-06 2015-05-14 Stemcentrx, Inc. Novel anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
HK1254743A1 (zh) 2019-07-26
BR112018011319A2 (pt) 2018-12-04
CL2018001481A1 (es) 2018-08-24
US20190083645A1 (en) 2019-03-21
SG11201804673WA (en) 2018-06-28
WO2017096163A1 (en) 2017-06-08
MA43385A (fr) 2018-10-10
MX2018006782A (es) 2018-11-09
DOP2018000138A (es) 2018-12-31
AU2016364853A1 (en) 2018-06-21
EP3383917A1 (en) 2018-10-10
ECSP18049762A (es) 2018-07-31
CA3006738A1 (en) 2017-06-08
EP3383917A4 (en) 2019-08-21
KR20180088445A (ko) 2018-08-03
IL259681A (en) 2018-07-31
CN108473588A (zh) 2018-08-31
RU2018124319A (ru) 2020-01-09
CO2018005752A2 (es) 2018-06-12
CR20180348A (es) 2018-08-23
PH12018501153A1 (en) 2019-01-28
JP2019500335A (ja) 2019-01-10
TW201726175A (zh) 2017-08-01
PE20181302A1 (es) 2018-08-09

Similar Documents

Publication Publication Date Title
CL2019000189A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
CR20150524A (es) Compuestos de heteroarilo y sus usos
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
AR101905A1 (es) Compuestos bicíclicos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa